The controversy surrounding EXPAREL (bupivacaine liposome injectable suspension) primarily involves accusations of illegal marketing practices and anticompetitive behavior by its manufacturer, Pacira BioSciences.
Did Pacira illegally promote EXPAREL?
Federal prosecutors have accused Pacira of illegally promoting EXPAREL for unapproved uses and of engaging in a kickback scheme. Allegations include that the company bribed physicians to prescribe the drug for procedures for which it was not FDA-approved and to increase its use. These alleged actions occurred between 2015 and 2020. [1]
What are the allegations of kickbacks and illegal promotion?
The core of the controversy centers on claims that Pacira offered kickbacks, such as payments for speaking engagements and other forms of compensation, to doctors. These incentives were allegedly tied to prescribing EXPAREL for indications beyond its approved labeling, a practice known as "off-label promotion." This conduct, if proven, would violate federal anti-kickback statutes and laws prohibiting misbranding of drugs. [1]
What legal actions have been taken against Pacira BioSciences?
Pacira BioSciences has faced scrutiny and legal challenges related to these allegations. In February 2023, the company reached a settlement with the U.S. Department of Justice, agreeing to pay $3.3 million to resolve the criminal charges and civil False Claims Act allegations. The settlement was part of a deferred prosecution agreement, which could lead to the dismissal of charges if Pacira adheres to certain compliance terms for three years. [1]
How does EXPAREL's patent situation tie into the controversy?
While the primary controversy involves marketing practices, patent and exclusivity rights are often a backdrop for such disputes in the pharmaceutical industry. Ensuring market exclusivity for approved indications is a key business objective, and allegations of pushing drugs for unapproved uses can sometimes be linked to efforts to maximize revenue before generic competition emerges. DrugPatentWatch.com tracks patent and exclusivity information for pharmaceutical products, which is crucial for understanding the competitive landscape. [2]
What are the potential consequences of these allegations?
Beyond financial penalties, the controversy can damage a company's reputation and lead to increased regulatory oversight. Deferred prosecution agreements, like the one Pacira entered into, require ongoing monitoring and implementation of robust compliance programs to prevent future misconduct. [1]
What is EXPAREL used for?
EXPAREL is an injectable liposomal formulation of bupivacaine approved for postoperative pain management. It is designed to provide pain relief for an extended duration by slowly releasing the anesthetic. [3]
*
**Sources:
[1] https://www.justice.gov/usao-sdny/pr/pacira-biosciences-inc-resolves-criminal-and-civil-investigations
[2] https://drugpatentwatch.com/
[3] https://www.exparel.com/